SCHEMBL4706532

SCHEMBL4706532

CCn1nc(-c2cccc(F)c2)c(C(C)=O)c(Nc2cccc(Br)c2)c1=O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 3/20 0.57
▸ MAPT P10636 1/20 0.37
▸ FPR1 P21462 1/20 0.36
▸ FPR2 P25090 1/20 0.36
▸ ALPL P05186 1/20 0.36
▸ ALPI P09923 1/20 0.36
▸ ALPG P10696 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ BRD4 O60885 1/20 0.35
▸ CREBBP Q92793 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ ADRA1D P25100 1/20 0.35
▸ ADRA1A P35348 1/20 0.35
▸ ADRA1B P35368 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4708777 0.93 PDE4B (0.62) PDE4BALPLALPIALPGSMN1; SMN2
SCHEMBL4706489 0.90 PDE4B (0.70) PDE4BMAPTSMN1; SMN2
SCHEMBL4706986 0.89 PDE4B (0.57) PDE4BMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL4706107 0.88 PDE4B (0.70) PDE4BSMN1; SMN2HTR1AADRA1DADRA1A
SCHEMBL4705775 0.87 PDE4B (0.58) PDE4B
SCHEMBL4709794 0.87 PDE4B (0.57) PDE4BSMN1; SMN2MEN1KMT2A
SCHEMBL4706044 0.86 PDE4B (0.55) PDE4BSMN1; SMN2MEN1KMT2A
SCHEMBL3033404 0.86 PDE4B (0.56) PDE4B
SCHEMBL4706440 0.85 PDE4B (0.54) PDE4BMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL4707445 0.85 PDE4B (0.62) PDE4BFPR1FPR2ALPLALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 — — US claimed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 — — US claimed
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 — — US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 — — US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885MAPT 3692/4885FPR1 4538/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885MAPT 3692/4885FPR1 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback